\
&
Contact us
\
&
Contact us
This was 1 month ago
LocationHybrid
This event is organised under the auspices of the Polish Presidency and comes at the time of the final adoption of the European Health Data Space (EHDS) regulation as well as a (re)statement of the Commission and Member States commitment to its successful implementation.
The event aims to highlight the transformative potential of the EHDS for the healthcare systems, emphasize the shared European vision for health data and provide a strong foundation for the successful implementation of the EHDS.
On the agenda:
- Panel 1: The promises of EHDS - A patient-centric initiative - Benefits for European citizens
- Panel 2: Building trust - privacy, security and patient engagement
- Panel 3: The promises of EHDS - Driving innovation and competetiveness in the Health sector
The event can be attended either in-person or online (via a live stream platform).
More information, the detailed agenda and registration can be found on the event's webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
